Head and Neck Neoplasm

Of 351 primary thyroid carcinoma patients assessed by targeted gene rearrangement next-generation assay, 11 cases (3.1%) had NTRK rearrangement. Only one case of EML4::NTRK3 fusion (e2,e13) with an in… (full text at CIViC)

PMID 32457407 · Chu et al., 2020 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Four of five… (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

In NCI-MATCH, patients with advanced solid tumors other than breast and gastro-esophageal tumors harboring ERBB2 amplification were treated with ad-trastuzumab emtansine (T-DM1). ERBB2 amplification w… (full text at CIViC)

PMID 31504139 · Jhaveri et al., 2019 · Open in CIViC

Case report of a 60-year old patient with p16 positive tumor of the tonsil with lung metastases after primary radiochemotherapy. The metastases were analyzed using a commercial molecular analysis and … (full text at CIViC)

PMID 28061634 · Seim et al., 2017 · Open in CIViC

In this single-center, single-arm, open-label, phase II study, 57 patients with HER2-positive (as defined by 3+ IHC staining or evidence of amplification by FISH) salivary duct carcinoma were treated … (full text at CIViC)

PMID 30452336 · Takahashi et al., 2019 · Open in CIViC

In an in vitro study, a head and neck squamous cell carcinoma cell line OSC-19 expressing ERBB2 (HER2) S1050L mutation was associated with insensitivity to cetuximab, afatinib, and erlotinib treatment… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

In an in vitro study, an head and neck squamous cell carcinoma (HNSCC) cell line KYSE270 expressing ERBB3 (HER3) R1202W mutation was associated with insensitivity to cetuximab and erlotinib treatments… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

This retrospective preclinical study assessed the efficacy of afatinib towards head-and-neck squamous cell carcinoma (HNSCC) human cell lines expressing ERBB4 (HER4) G1109C mutation. According to the … (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

In an in vitro study, a head and neck squamous cell carcinoma cell line SAS expressing ERBB4 (HER4) G1109C was associated with insensitivity to erlotinib treatment (IC50=1.47uM). Resistance was determ… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

A 53 year old female patient had PTC treated with surgery and multiple brain metastases. TERT c.-124C.T mutation and ETV6::NTRK2 fusion was found in pleural biopsy and cerebellar resection specimens.… (full text at CIViC)

PMID 35171659 · Park et al., 2022 · Open in CIViC

Prasad et al queried the histopathology of 28 Papillary Thyroid Carcinomas (PTCs) from patients ages 6-18 years (20 females, 8 males). None had significant exposure to radiation. 5 / 27 PTCs (18.5%) h… (full text at CIViC)

PMID 26784937 · Prasad et al., 2016 · Open in CIViC

A comprehensive molecular profiling (whole exome and whole transcriptome sequencing) determined that CTNNB1 I35T and FBXW11 F517S missense mutations were mutually exclusive and collectively account fo… (full text at CIViC)

PMID 40389436 · Wong et al., 2025 · Open in CIViC

Expression of bFGF and FGFR1 were evaluated in 61 biopsy specimens of primary OSCC (IHC). Expression was evaluated in both the cancer cells and fibroblasts at the invasive front of each tumor. bFGF an… (full text at CIViC)

PMID 16454808 · Hase et al., 2006 · Open in CIViC

This review identified 12 studies that addressed the prognostic role of FGFRs in HNSSC. The authors conclude that evidence was found for prognostic value of FGFR1 expression in cancer-associated fibro… (full text at CIViC)

PMID 26115874 · Ipenburg et al., 2016 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

FGFR2 p.P253R mutation detected in patient with head and neck SCC. Mutation initially detected by RNA-Seq and confirmed by Sanger sequencing. Patient is 52 y/o male with initial diagnosis of SCC of … (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

In the phase II NCI-MATCH EAY131-K2 trial, a patient with high-grade adenoid cystic carcinoma of the submandibular gland harboring an FGFR2 S252W (p.Ser252Trp) mutation achieved a partial response to … (full text at CIViC)

PMID 38603650 · Gong et al., 2024 · Open in CIViC

Paper analysing FGFR3-TACC3 frequency and oncogenicity in nasopharyngeal carcinoma. FGFR3-TACC3-K508M in HNE1 and HK1 NPC cell lines showed a significant reduction of cellular proliferation in the col… (full text at CIViC)

PMID 25535896 · Yuan et al., 2014 · Open in CIViC

128 patients with oral squamous cell carcinoma (OSCC) and 145 normal control subjects were evaluated for the concentration of GAS6 in their plasma serum. OSCC patients were found to be associated with… (full text at CIViC)

PMID 26207647 · Jiang et al., 2015 · Open in CIViC

A 79 year old patient with prior 5-year history of Graves' disease presented with follicular thyroid carcinoma. Two mutations NRAS p.Q61K and GNAS p.R201H were detected. The thyroid cancer manifested … (full text at CIViC)

PMID 26788326 · Lu et al., 2016 · Open in CIViC

In an in vitro study, a H31 cell line expressing HRAS G12D mutation demonstrated decreased sensitivity to erlotinib treatment (GI50s >3.50 uM vs. 0.067�0.184 uM) compared to UM-SCC-19 or MSK-922 or M… (full text at CIViC)

PMID 24123531 · Hah et al., 2014 · Open in CIViC

In this preclinical study, cell lines with constitutively-active G12V mutant found that forced overexpression of HRAS G12V caused a reduced susceptibility to PI3K inhibitor BYL719 in comparison to wil… (full text at CIViC)

PMID 30115483 · Ruicci et al., 2018 · Open in CIViC

In an in vitro study, UM-SCC-10B, UM-SCC-22A and HN5 cell lines expressing HRAS G12V mutation demonstrated decreased sensitivity to erlotinib treatment compared to the respective sensitive parental ce… (full text at CIViC)

PMID 24123531 · Hah et al., 2014 · Open in CIViC

In an in vitro study, a C643 cell line expressing HRAS G13R demonstrated reduced sensitivity to vemurafenib treatment, compared to BRAF V600E expressing cells (8505C, SWI1736, BHT101 and BCPAP). Sensi… (full text at CIViC)

PMID 19880792 · Salerno et al., 2010 · Open in CIViC

In a phase II HNSCC trial, an objective response rate of 55% was seen in HRAS-mutant patients (11 of 20) treated with the farnesyltransferase inhibitor tipifarnib with a PFS of 5.6 months and an OS of… (full text at CIViC)

PMID 33750196 · Ho et al., 2021 · Open in CIViC

Follicular thyroid cancers harboring RAS mutations have limited aggressiveness in the absence of TERT mutations. 2/2 follicular thyroid cancer patients with co-mutations in NRAS (10 Q61R and 1 Q61K) o… (full text at CIViC)

PMID 25448848 · Muzza et al., 2015 · Open in CIViC

Within a preclinical study 15 patient samples with adenoid cystic carcinoma MYB-NFIB fusion activation loop can be modulated through AKT-dependent signaling induced by IGF1R overexpression and downreg… (full text at CIViC)

PMID 28954282 · Andersson et al., 2017 · Open in CIViC

Case report of a 62-year old male patient diagnosed with pancreatic acinar cell carcinoma. Liver metastases were diagnosed and treatment was started with gemcitabine plus nab-paclitaxel regimen. After… (full text at CIViC)

PMID 35005993 · Gaule et al., 2022 · Open in CIViC

Molecularly guided treatment with imatinib in analogy to the management of gastrointestinal stromal tumor (GIST) resulted in a dramatic and durable response with remission of nearly all tumor manifest… (full text at CIViC)

PMID 27687311 · Dieter et al., 2017 · Open in CIViC

TPO-CRE mediated, thyroid specific KRAS G12D expression was unable to tranform thyroid follicular cells alone, indicating these mutations require co-operating events to cause invasion and metastatic d… (full text at CIViC)

PMID 19351816 · Miller et al., 2009 · Open in CIViC

In an in vitro study, a thyroid cancer cell line, CAL62, which harbors the KRAS G12R mutation, was associated with increased sensitivity to dasatinib treatment (IC50: 35nM). Sensitivity was determined… (full text at CIViC)

PMID 22740998 · Chan et al., 2012 · Open in CIViC

In an in vitro study, a CAL62 cell line expressing KRAS G12R demonstrated reduced sensitivity to vemurafenib treatment, compared to BRAF V600E expressing cells (8505C, SWI1736, BHT101 and BCPAP). Sens… (full text at CIViC)

PMID 19880792 · Salerno et al., 2010 · Open in CIViC

In the retrospective analysis of 103 HNSSC, the TG/GG rs61764370 variant was associated with poor response to cisplatin (log-rank P = 0.002).There seemed to be some improvement when cetuximab was adde… (full text at CIViC)

PMID 25081901 · Chung et al., 2014 · Open in CIViC

In a clinical trial including 78 patients, expression of delta5 is significantly associated with decreased OS (p = 0.02) and DFS (p = 0.01) by multivariate analysis.

PMID 30770730 · Rot et al., 2019 · Open in CIViC

A stage IVA head and neck squamous cell carcinoma patient with MAPK1 E322K mutation was reported to be sensitive to erlotinib treatment. The patient was treated with erlotinib monotherapy daily for 13… (full text at CIViC)

PMID 26181029 · Van Allen et al., 2015 · Open in CIViC

Case report of a patient with stage IVA HNSCC with near-complete histologic response after 13 days of neoadjuvant erlotinib. Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mu… (full text at CIViC)

PMID 26181029 · Van Allen et al., 2015 · Open in CIViC

In an in vitro study, a HSC-6 cell line expressing MAPK1 E322K mutation was associated with sensitivity to erlotinib treatment, compared to Cal33 cells expressing wild-type MAPK1. Sensitivity was dete… (full text at CIViC)

PMID 27004400 · Wen et al., 2016 · Open in CIViC

66 HNSCC patients treated with chemoradiation were assessed for survival after a follow-up time of 10 years. Median OS was significantly shorter in patients with MDM2 SNP309 GG or GT genotypes compare… (full text at CIViC)

PMID 26916894 · Vivenza et al., 2016 · Open in CIViC

Two patients diagnosed with oncocytic thyroid carcinoma (hurthle cell thyroid carcinoma) were evaluated for MEN1 mutations. One tumor showed 592-end deletion of MEN1 and the other showed a 521 frames… (full text at CIViC)

PMID 25625803 · Kasaian et al., 2015 · Open in CIViC

A patient with platinum-refractory oral cavity head and neck squamous carcinoma underwent comprehensive genomic profiling that identified an activating MET R1004G mutation. The patient showed a rapid … (full text at CIViC)

PMID 31391294 · Chu et al., 2019 · Open in CIViC

After an 18-month sustained response to everolimus (in a patient with metastatic anaplastic thyroid carcinoma whose pretreatment tumor harbored a TSC2 Q1178* inactivating mutation, see EID1108), the r… (full text at CIViC)

PMID 25295501 · Wagle et al., 2014 · Open in CIViC

This study shows a significant antitumor effect of concurrent NBN downregulation (and MRN complex disruption) and PARP inhibition on HNSCC cells.

PMID 25324139 · Lajud et al., 2014 · Open in CIViC

The variant was diagnosed by WES in 4 family members with familial non-medullary thyroid carcinoma (FNMTC), in three consecutive generations.

PMID 34941562 · de Mello et al., 2022 · Open in CIViC

NF2 loss promotes oncogenic RAS-signaling via YAP-dependent transactivation of RAS and sensitizes to MEK inhibition. The authors demonstrate this in (A) isogenic lines derived from C643 cells (HRASG13… (full text at CIViC)

PMID 26359368 · Garcia-Rendueles et al., 2015 · Open in CIViC

Ten patients with Neurofibromatosis 2 were enrolled for treatment with Everolimus. At 12 months, no patients had reduction in tumor volume >20%, however, five patients had stable disease with a reduc… (full text at CIViC)

PMID 25567352 · Goutagny et al., 2015 · Open in CIViC

In a phase II, nonrandomized, single-arm trial (NCT03740100), 8 patients with recurrent/metastatic HNSCC harboring NOTCH1 mutations predicted to cause loss of function received bimiralisib after prior… (full text at CIViC)

PMID 36124629 · Johnson et al., 2022 · Open in CIViC

In an evaluation of 96 head and neck squamous cell carcinoma (HNSCC) cell lines, 31 were responsive to LGK974 (PORCN inhibitor). Of 40 cell lines (25 responsive, 15 non-responsive) that were exome seq… (full text at CIViC)

PMID 24277854 · Liu et al., 2013 · Open in CIViC